Tolerance and short-term effect of a cluster schedule with pollen-extracts quantified in mass-units

• Autores: Francisco Guerra Pasadas, Carmen Moreno Aguilar, José Luis Justicia Ruano, José Vigaray Conde, S Acero, Ricardo Blanco Alonso, J. Conde, Consuelo Martínez Cócera, Fernando de la Torre Morín, Mercedes Cimarra Alvarez, María Ángeles Gonzalo Garijo, P. Guardia, Manuel Díaz Fernández, T. González Quevedo, M. Sánchez Cano, Remedios Pérez Calderón
• Localización: Allergologia et immunopathologia: International journal for clinical and investigate allergology and clinical immunology, ISSN-e 1578-1267, ISSN 0301-0546, Vol. 32, Nº. 5, 2004, págs. 271-277
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • We performed a prospective, multicenter study to assess the tolerance and possible short-term effects of allergen vaccines administered according to a cluster schedule in the months immediately preceding the onset of the pollen season.

    The study was carried out in eight centers and included 191 patients (children and adults) with allergic respiratory disease due to sensitization to olive tree and/or grass pollen. Of these, 34 patients acted as controls and the remaining patients received immunotherapy administered in the initiation phase according to a cluster schedule of eight doses injected on four visits. After 3 months of treatment, significant differences were found between the two groups in medication consumption (antihistamines in drops and oral formulations: p = 0.045 and p = 0.001, respectively; short-acting ß2-agonist treatments: p = 0.004) and respiratory symptoms (wheezing and coughing: p = 0.035 and 0.014, respectively). The cytokine profile (interleukin [IL]-4, 5, 10 and 2, interferon [IFN-?], and tumor necrosis factor [TNF-a]) was determined before the start of treatment and at the end of follow-up (4-5 months). Levels of IL-4, 5 and 10 (Th2 profile) decreased while those of IL-2, IFN-?, and TNF-a (Th1 profile) decreased. These differences were more marked in the active group than in the control group but were not statistically significant. No severe adverse effects were recorded. This study shows that the schedule tested had an acceptable tolerance profile and produced significant changes in symptom and medication scores after a few months of treatment. A double-blind, placebo-controlled study is needed to confirm these results.